wtx-330
Recombinant proteinexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 6, 2022 (NCT05678998)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-12 subunit betaSupplementation
IL12B supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06939283 | Phase 1/Phase 2 (Phase 2) | May 7, 2025 | Werewolf Therapeutics, Inc. |
| NCT05678998 | Phase 1 | Dec 6, 2022 | Werewolf Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Werewolf Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2022 |
1 organizations
Page 1 / 1